Shots:
- The first patient has been dosed in P-Ib trial evaluating SpringWorks’ Nirogacestat (GSI) + Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. Janssen assumes all costs of study & other expenses related to the supply of nirogacestat
- In preclinical models, Nirogacestat increased the cell surface density of BCMA, reduced the levels of soluble BCMA and enhanced the activity of BCMA-targeted therapies
- SpringWorks has formed a joint oversight committee with Janssen to manage study results, regulatory and other activities and is currently conducting a global P-III DeFi trial assessing nirogacestat vs PBO in adults with progressing desmoid tumors
Click here to read full press release/ article | Ref: GlobeNewswire | Image: BusinessWire
The post Janssen and SpringWorks Reports Dosing of First Patient in P-Ib trial for Nirogacestat + Teclistamab to Treat Relapsed or Refractory Multiple Myeloma first appeared on PharmaShots.
